Research suggests that the appetite suppressing drug semaglutide could transform treatment for many with the cardiac condition, which affects a million people in Britain
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.
Atrial fibrillation and heart failure may arise from the same common soil of pathogenic mechanisms, rather than one begetting the other, European researchers propose.